Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring

Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias... American Journal of Therapeutics 21, 254–259 (2014) Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring Rune Erichsen, MD,* Ellen Mikkelsen, PhD, Lars Pedersen, PhD and Henrik Toft Sørensen, MD Proton pump inhibitors (PPIs) are increasingly used in reflux disease treatment also among pregnant women. Hypospadias prevalence is increasing and the birth defect is diagnosed in 0.3%–0.8% of male births, but the association with maternal PPI use during pregnancy is virtually unknown. Therefore, we decided to estimate the hypospadias risk in male offspring after maternal PPI use during pregnancy. We used Danish nationwide registries to conduct a population-based prevalence study including all live-born boys from 1997 through 2009. Maternal PPI use was classified according to exposure time: early pregnancy (30 days before conception through the end of the first trimester) and entire pregnancy (30 days before and throughout pregnancy). Outcome was defined as a hospital hypospadias diagnosis recorded any time after delivery. We calculated prevalence ratios and 95% confidence intervals associating maternal PPI use with hypospadias in male offspring using Cox proportional hazard regression analysis and adjusted for confounding factors. We identified a total of 430,569 live-born boys of whom 2926 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Therapeutics Wolters Kluwer Health

Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring

Loading next page...
 
/lp/wolters-kluwer-health/maternal-use-of-proton-pump-inhibitors-during-early-pregnancy-and-the-u0srmy4FUQ

References (23)

Copyright
Copyright © 2012 by Lippincott Williams & Wilkins
ISSN
1075-2765
eISSN
1536-3686
DOI
10.1097/MJT.0b013e3182456a8f
pmid
22314213
Publisher site
See Article on Publisher Site

Abstract

American Journal of Therapeutics 21, 254–259 (2014) Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring Rune Erichsen, MD,* Ellen Mikkelsen, PhD, Lars Pedersen, PhD and Henrik Toft Sørensen, MD Proton pump inhibitors (PPIs) are increasingly used in reflux disease treatment also among pregnant women. Hypospadias prevalence is increasing and the birth defect is diagnosed in 0.3%–0.8% of male births, but the association with maternal PPI use during pregnancy is virtually unknown. Therefore, we decided to estimate the hypospadias risk in male offspring after maternal PPI use during pregnancy. We used Danish nationwide registries to conduct a population-based prevalence study including all live-born boys from 1997 through 2009. Maternal PPI use was classified according to exposure time: early pregnancy (30 days before conception through the end of the first trimester) and entire pregnancy (30 days before and throughout pregnancy). Outcome was defined as a hospital hypospadias diagnosis recorded any time after delivery. We calculated prevalence ratios and 95% confidence intervals associating maternal PPI use with hypospadias in male offspring using Cox proportional hazard regression analysis and adjusted for confounding factors. We identified a total of 430,569 live-born boys of whom 2926

Journal

American Journal of TherapeuticsWolters Kluwer Health

Published: Jul 1, 2014

There are no references for this article.